EFFISSIMO-CAPITAL-MGMT
1.3.2021 08:02:12 CET | Business Wire | Press release
Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021.
The full proposal in English can be found here .
Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address.
The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator to have been delivered past the AGM deadline and not counted. It also examines the artificially limited scope and conclusions of Toshiba’s Audit Committee’s investigations into shareholder pressure and vote tampering allegations.
Finally, the presentation provides a detailed historical context of chronic governance and oversight dysfunction at Toshiba that has persisted despite the installation of new management in 2017.
Vote Delivery & Tabulation
- Inexplicable Delay in Ballot Delivery: Effissimo’s own field tests and review of other Japanese companies’ AGMs confirm Japan Post, in accordance with its own service guidelines, normally takes at most three days to deliver domestic mail. But Toshiba’s vote tabulator insists that it took four days, in breach of Postal Law, for ballots to be delivered.
- Uncounted Ballots: There are still nearly 1,000—but possibly more than 1,600—additionally reported ballots that have yet to be audited by the Audit Committee due to claims they were delivered too late to be counted. These ballots should have ordinarily arrived prior to the vote deadline, absent the inexplicable delay in ballot delivery.
- Treatment of Blank Ballots: Mailed ballots made up more than one-third of Toshiba’s quorum at the AGM – a substantial portion of shareholder participation. Roughly 17% of ballots were blank, which Toshiba treated as favorable to management. While lawful, this is clearly an anti-dissident practice that Toshiba could have abandoned after a shareholder proposal in this regard back in 2015.
Shareholder Pressure
- Decline in Shareholder Participation: In a closely contested vote that attracted intense interest and attention, participation at the AGM declined by three percentage points year-over-year, providing grounds for suspicion that voter suppression in fact occurred.
- Multiple Institutional Investors Absent from AGM: Credible media outlets have reported that shareholders were “pressured” and/or “threatened” with a probe if they voted against Toshiba management. Toshiba’s voting records indicate that some institutional shareholders that normally vote as a matter of course did not vote at the AGM. Effissimo’s confidential survey confirmed that multiple shareholders were pressured.
Although it may appear complex, the heart of issue is simple. Effissimo believes there should be an independent investigation as opposed to a self-audit by a conflicted Audit Committee.
The Audit Committee, chaired by a director whose reappointment was opposed by more than 40 percent of shareholders at the AGM, is conflicted and is naturally reticent to conduct an uninhibited investigation of possible wrongdoing at the AGM. This conflict manifests itself in the Audit Committee’s reviews and investigations, which we suspect are deliberately limited in scope at the outset to produce a pre-determined result.
The right to vote is what is at stake. Shareholders must not passively accept the Board’s explanations at face value and allow the status quo of weak governance to persist. Failure to perform a thorough and independent investigation will set a harmful precedent not only for Toshiba but also for corporate Japan as a whole.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210228005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings & Gatbits IT Infrastructure Announce Launch of GTBS Digital Ecosystem; Mainnet Set for April 202630.3.2026 20:30:00 CEST | Press release
The Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings, in collaboration with Gatbits IT Infrastructure, has officially announced the launch of the GTBS Digital Ecosystem, marking a significant step forward in the global Web3 space. The announcement follows the successful launch of the native GTBS Coin on December 25, with the ecosystem’s mainnet scheduled to go live in April 2026. GTBS represents a full-stack Web3 ecosystem integrating blockchain, artificial intelligence, decentralized finance (DeFi), entertainment, gaming, media, and cloud infrastructure into a unified platform. Built on the philosophy of “All Commitment On Time,” the ecosystem focuses on delivering reliability, scalability, and real-world utility. Designed as a comprehensive digital infrastructure, GTBS goes beyond standalone crypto platforms by offering an integrated environment for users, developers, creators, and enterprises. Its proprietary Layer-1 blockchain powers seamless interaction across se
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
